An international research team led by RIKEN has identified associations between pathogenic variants of BRCA 1 and 2 genes and four previously unstudied cancer types. This discovery expands the potential for personalized medicine, particularly with PARP inhibitors and specific chemotherapies, to a wider range of cancers with currently limited treatment options and poor prognoses. The study analyzed data from BioBank Japan, comparing BRCA variants in patients with bladder, bone, brain, head and neck, sarcoma, skin, testis, thyroid, and ureteral cancers against a control group.
RIKENApr 17 2026 An international group led by researchers from the RIKEN Center for Integrative Medical Sciences in Japan have discovered associations between pathogenic variants of the BRCA 1 and 2 genes and four types of cancer.
Published in ESMO Open, the findings expand the potential for personalized medicine to several cancer types that currently have limited treatment options and poor prognoses. Pathogenic variants of the BRCA genes are well known to be associated with the risk of breast cancer, as well as ovarian, pancreatic, and prostate cancer. As a result, personalized medicine for these types of cancer using PARP inhibitors—a type of drug that kills cancer cells by preventing them from repairing their DNA—or certain chemotherapeutic drugs has become routine in clinical practice. For most other less common cancers, the BRCA association has yet to be studied. The goal of the new study was to fill in this missing information gap and determine whether the potential for BRCA-based personalized medicine exists for other types of cancer. To start with, the researchers performed a case-control analysis of 3,489 patients whose data was taken from BioBank Japan, a multi-institutional, hospital-based registry of blood samples from all over Japan taken between 2003 and 2018. This type of analysis involves looking at people with and without a particular disease and identifying factors that could have led to different clinical outcomes. In this case they focused on nine types of cancer that have yet to be tested for a BRCA-gene association, namely bladder, bone, brain, head and neck, sarcoma, skin, testis, thyroid, and ureteral cancer. They compared the BRCA variants of the patients with those of 38,842 individuals from the same database who did not have cancer. From the analysis, they found that pathogenic variants in BRCA1 increase the risk of thyroid cancer, while pathogenic variants in BRCA2 increase the risk of bladder cancer, head and neck cancer, and skin cancer. For bladder cancer, they found that the impact of BRCA2 pathogenic variants on cancer risk was greater in women than in men. In the world of medical research, resources, both funding and manpower, are often skewed toward the most common and most deadly diseases. As a result, people with less common diseases are often out of luck when it comes to clinical trials or new treatment options. According to Hajime Sasagawa, the first author of the paper, "While previous studies have expanded the cancer risk profile associated with BRCA1/2 pathogenic variants to ovarian, pancreatic, and prostate cancer, we felt that relatively less common cancer types would also benefit from an expansion of genetic evidence, particularly because of their limited treatment options and poor prognoses. I am happy that we were able to gain these new insights." I am happy that we have been able to gain these new insights. Although this study will not lead to immediate recommendations for active surveillance of those cancer types, we hope that these findings will contribute to the development of personalized medicine guidelines for these four types of cancer." Previous to the current study, the group has revealed a number of new BRCA-related cancers in a study published in JAMA Oncology in 2022 and on genome and environmental interactions in the New England Journal of Medicine in 2023.
BRCA Genes Cancer Personalized Medicine Genetics PARP Inhibitors
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ships Defy Trump's Strait of Hormuz Blockade, Including Vessels Linked to Iran and ChinaDespite Donald Trump's blockade of the Strait of Hormuz, numerous ships, including those linked to Iran and China, have sailed through the waterway. The US has threatened to sink ships defying the blockade, while multiple vessels have ignored the warning. Data indicates activity from Iran and China-linked vessels. This follows the US military's announcement of a fully implemented blockade of Iranian ports.
Read more »
Baby's Death Linked to Antihistamine, Coroner Rules; Police Investigation CriticizedAn eight-week-old baby died after being given an antihistamine, likely to sedate him, according to a coroner's ruling. The investigation into the death was criticized for missing crucial forensic evidence. The coroner also raised concerns about the lack of national regulation for nannies and the individual continuing to work in childcare.
Read more »
Loneliness is linked to higher risk of degenerative heart valve diseaseAdults who reported feeling lonely had a higher risk of developing degenerative heart valve disease, even after accounting for traditional heart disease risk factors and genetics, according to new research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.
Read more »
Breakthrough blood test predicts kidney failure years before clinical symptomsA new blood test can identify which individuals of African ancestry carrying high-risk APOL1 gene variants are most likely to develop kidney failure, years before clinical disease becomes apparent.
Read more »
Burglaries in Lisburn area may be linked as PSNI issue description of suspectA man was also reported to have been seen attempting to open cars in the Hillview Avenue area
Read more »
New RNA sequencing method improves rare disease diagnosisResearchers from Children's Hospital of Philadelphia (CHOP) developed a new RNA sequencing strategy that can reveal how genetic variants disrupt gene function and improve the diagnosis of rare diseases.
Read more »